Published in Ann Rheum Dis on March 27, 2007
Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum (2009) 2.50
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 1.84
Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. J Rheumatol (2015) 1.40
Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol (2012) 1.27
Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block. J Immunol (2010) 1.26
Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther (2009) 1.20
Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation (2012) 1.20
Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha. Clin Immunol (2012) 1.09
The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol (2011) 1.09
New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol (2012) 1.07
Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus (2012) 1.05
Management of cardiovascular disease risk in chronic inflammatory disorders. Nat Rev Rheumatol (2009) 0.98
Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 0.97
Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol (2011) 0.96
Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution. Arthritis Rheum (2009) 0.96
Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States. Arthritis Care Res (Hoboken) (2014) 0.94
Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford) (2008) 0.92
Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology (Oxford) (2009) 0.89
Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis (2007) 0.88
Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. Arthritis Care Res (Hoboken) (2010) 0.87
Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis (2012) 0.86
Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics (Sao Paulo) (2013) 0.86
How can we reduce the risk of serious infection for patients with systemic lupus erythematosus? Arthritis Res Ther (2009) 0.85
Update on systemic lupus erythematosus pregnancy. J Prenat Med (2010) 0.85
Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort. Lupus (2009) 0.83
Cardiovascular involvement in autoimmune diseases. Biomed Res Int (2014) 0.82
Identification of activators of ERK5 transcriptional activity by high-throughput screening and the role of endothelial ERK5 in vasoprotective effects induced by statins and antimalarial agents. J Immunol (2014) 0.82
Association of discoid lupus erythematosus with clinical manifestations and damage accrual in a multiethnic lupus cohort. Arthritis Care Res (Hoboken) (2012) 0.80
Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. Autoimmune Dis (2013) 0.80
Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol (2016) 0.79
Healthcare quality in systemic lupus erythematosus: using Donabedian's conceptual framework to understand what we know. Int J Clin Rheumtol (2012) 0.78
[Antimalarials. A treatment option for every lupus patient!?]. Z Rheumatol (2009) 0.76
Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences. Medicine (Baltimore) (2015) 0.76
Prognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort. PLoS One (2016) 0.75
Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood. Future Sci OA (2015) 0.75
Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study. Clin Rheumatol (2014) 0.75
Immunomodulators in SLE: Clinical evidence and immunologic actions. J Autoimmun (2016) 0.75
Violacein Treatment Modulates Acute and Chronic Inflammation through the Suppression of Cytokine Production and Induction of Regulatory T Cells. PLoS One (2015) 0.75
Why targeted therapies are necessary for systemic lupus erythematosus. Lupus (2016) 0.75
TSG-6 Downregulates IFN-Alpha and TNF-Alpha Expression by Suppressing IRF7 Phosphorylation in Human Plasmacytoid Dendritic Cells. Mediators Inflamm (2017) 0.75
Hydroxychloroquine-Induced Erythema Multiforme. J Clin Rheumatol (2017) 0.75
Current and emerging treatment options in the management of lupus. Immunotargets Ther (2016) 0.75
Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions. Int J Clin Rheumtol (2015) 0.75
Lupus nephritis in children - 10 years' experience. Cent Eur J Immunol (2016) 0.75
The Cutaneous Spectrum of Lupus Erythematosus. Clin Rev Allergy Immunol (2017) 0.75
[Modern therapy for systemic lupus erythematosus]. Z Rheumatol (2007) 0.75
Survival analysis of patients with systemic lupus erythematosus in a tertiary hospital in southern Brazil. Clin Rheumatol (2017) 0.75
The Sarawak lupus cohort: clinical features and disease patterns of 633 SLE patients in a single tertiary centre from East Malaysia. Rheumatol Int (2014) 0.75
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1997) 43.47
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med (1998) 32.43
Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum (2005) 4.64
A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. N Engl J Med (1991) 3.12
Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum (2003) 2.97
Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum (2001) 2.68
Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology (2002) 2.51
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum (2001) 2.13
How frequently and how soon should we screen our patients for the presence of antimalarial retinopathy? Arthritis Rheum (2002) 2.09
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus (1998) 1.93
The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum (2003) 1.84
Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med (1991) 1.79
Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus (2006) 1.66
Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum (2005) 1.64
The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 1.55
Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. Arthritis Rheum (1995) 1.52
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus (1996) 1.41
Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology (Oxford) (2003) 1.36
Divergent racial trends in mortality from systemic lupus erythematosus. J Rheumatol (1995) 1.05
High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol (2002) 1.03
Antimalarials--the 'real' advance in lupus. Lupus (2001) 0.97
Discontinuation of antimalarial drugs in systemic lupus erythematosus. J Rheumatol (1999) 0.88
Systemic lupus erythematosus in a multiethnic U.S. cohort (LUMINA) XXXI: factors associated with patients being lost to follow-up. Lupus (2006) 0.87
The effects of ethnicity on disease patterns in 472 Orientals with systemic lupus erythematosus. J Rheumatol (1998) 0.86
Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL). Lupus (2006) 0.85
Reduction of sampling bias of odds ratios for vertebral fractures using propensity scores. Osteoporos Int (2005) 0.83
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum (2008) 13.08
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet (2009) 5.75
Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med (2013) 5.67
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet (2011) 5.56
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med (2013) 3.81
Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet (2010) 3.58
A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum (2002) 3.55
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.51
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Gene and pathway-based second-wave analysis of genome-wide association studies. Eur J Hum Genet (2010) 3.03
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet (2013) 2.87
A comparison of the abilities of nine scoring algorithms in predicting mortality. J Trauma (2002) 2.70
Can high-risk older drivers be identified through performance-based measures in a Department of Motor Vehicles setting? J Am Geriatr Soc (2006) 2.67
Impact of cataract surgery on motor vehicle crash involvement by older adults. JAMA (2002) 2.67
Timed instrumental activities of daily living tasks: relationship to cognitive function and everyday performance assessments in older adults. Gerontology (2002) 2.61
Identifying risk for massive transfusion in the relatively normotensive patient: utility of the prehospital shock index. J Trauma (2011) 2.59
Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet (2011) 2.54
Association between depression and functional vision loss in persons 20 years of age or older in the United States, NHANES 2005-2008. JAMA Ophthalmol (2013) 2.52
Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum (2009) 2.50
Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet (2010) 2.44
Sheathotomy to decompress branch retinal vein occlusion: a matched control study. Ophthalmology (2004) 2.43
Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence. Arthritis Rheum (2013) 2.42
The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum (2013) 2.40
Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm. Arch Ophthalmol (2006) 2.36
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2010) 2.30
A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum (2007) 2.24
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther (2008) 2.15
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
Human chorioretinal layer thicknesses measured in macula-wide, high-resolution histologic sections. Invest Ophthalmol Vis Sci (2011) 2.13
Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol (2009) 2.13
Negative pressure wound therapy after severe open fractures: a prospective randomized study. J Orthop Trauma (2009) 2.10
Cognitive training decreases motor vehicle collision involvement of older drivers. J Am Geriatr Soc (2010) 2.08
Age of transfused blood: an independent predictor of mortality despite universal leukoreduction. J Trauma (2008) 2.07
Discrimination between glaucomatous and nonglaucomatous eyes using quantitative imaging devices and subjective optic nerve head assessment. Invest Ophthalmol Vis Sci (2006) 2.05
The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma (2009) 2.03
Association between side-impact airbag deployment and risk of injury: A matched cohort study using the CIREN and the NASS-CDS. J Trauma Acute Care Surg (2012) 2.01
Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics (2008) 1.89
Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis (2009) 1.84
Validity, reproducibility, and responsiveness of a twelve-joint simplified power doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthritis Rheum (2008) 1.80
Vision and driving. Vision Res (2010) 1.80
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum (2004) 1.75
On-road driving performance by persons with hemianopia and quadrantanopia. Invest Ophthalmol Vis Sci (2008) 1.74
Transfusions in the less severely injured: does age of transfused blood affect outcomes? J Trauma (2008) 1.73
Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum (2005) 1.64
Fatal work-related inhalation of harmful substances in the United States. Chest (2002) 1.64
Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum (2008) 1.64
Perceived barriers to care and attitudes about vision and eye care: focus groups with older African Americans and eye care providers. Invest Ophthalmol Vis Sci (2006) 1.64
New population-based reference values for spinal mobility measures based on the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Rheumatol (2014) 1.64
Hypothyroidism and the development of open-angle glaucoma in a male population. Ophthalmology (2004) 1.63
End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol (2014) 1.62
Non-arteritic anterior ischaemic optic neuropathy and presumed sleep apnoea syndrome screened by the Sleep Apnea scale of the Sleep Disorders Questionnaire (SA-SDQ). Br J Ophthalmol (2007) 1.59
Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J Med Genet (2014) 1.58
Glaucoma after ocular contusion: a cohort study of the United States Eye Injury Registry. J Glaucoma (2005) 1.58
Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol (2002) 1.57
The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther (2003) 1.56
Bovine polymerized hemoglobin (hemoglobin-based oxygen carrier-201) resuscitation in three swine models of hemorrhagic shock with militarily relevant delayed evacuation--effects on histopathology and organ function. Crit Care Med (2006) 1.54
Duration of red cell storage influences mortality after trauma. J Trauma (2010) 1.54
Vascular injuries in knee dislocations: the role of physical examination in determining the need for arteriography. J Bone Joint Surg Am (2004) 1.53
Negative pressure wound therapy to treat hematomas and surgical incisions following high-energy trauma. J Trauma (2006) 1.52
Acute kidney injury reduces survival in very low birth weight infants. Pediatr Res (2011) 1.51
Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor. Arthritis Rheum (2007) 1.51
On-road driving with moderate visual field loss. Optom Vis Sci (2005) 1.51
Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther (2010) 1.50
Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet (2011) 1.49
Cone- and rod-mediated dark adaptation impairment in age-related maculopathy. Ophthalmology (2007) 1.49
Subretinal drusenoid deposits in non-neovascular age-related macular degeneration: morphology, prevalence, topography, and biogenesis model. Retina (2013) 1.49
Association between retinal thickness measured by spectral-domain optical coherence tomography (OCT) and rod-mediated dark adaptation in non-exudative age-related maculopathy. Br J Ophthalmol (2011) 1.48
Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Ann Rheum Dis (2006) 1.47
Evaluation of the relationship between ablation diameter, pupil size, and visual function with vision-specific quality-of-life measures after laser in situ keratomileusis. Arch Ophthalmol (2007) 1.47
Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis (2006) 1.47
Acute kidney injury is independently associated with mortality in very low birthweight infants: a matched case-control analysis. Pediatr Nephrol (2009) 1.47
Factors associated with chronic renal failure in HIV-infected ambulatory patients. AIDS (2004) 1.45
Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis. J Rheumatol (2013) 1.45
Effect of refractive error correction on health-related quality of life and depression in older nursing home residents. Arch Ophthalmol (2007) 1.45